Medical Therapy

in Lower Extremity Arterial Disease

Applied

Type

Modification

Confidence

92%

Created

Apr 26, 2026

Evidence

1 source

Rationale

The 2026 ACC/AHA Lower Extremity PAD guideline (PMID 41252847) supersedes the previously cited acc 2025 b for the same claim regarding diabetes management targets (HbA1c <7%). Per the stale guideline replacement instructions, acc 2025 b has been replaced with ACC/AHA for that claim. Additionally, the LDL target recommendation in the statin therapy bullet was reinforced with ACC/AHA as the superseding guideline covers lipid management targets for PAD patients. No other substantive content changes were required as the remaining claims are supported by their existing citations.

Evidence

ACC/AHA. Management of Lower Extremity Peripheral Artery Disease: Guidelines From the ACC/AHA. 2026. PMID: 41252847.
Verified source
PubMedDOI

Content Changes

* **Risk factor modification:** smoking cessation (most critical intervention)[@willigendael2004, @armstrong2014], blood pressure control (target <130/80 mmHg), optimal diabetes management (hemoglobin A1c [HbA1c] <7%) [@acc2025-b],[@acc2026-b], and lipid management.[@ahaacc2016]
* **Supervised exercise therapy (SET):** structured walking programs (3 sessions/week, 30–60 minutes) improve claudication distance by 50–200% and remain a Class I recommendation [@lane2017, @conte2025]. Recent systematic reviews confirm SET as a primary non-invasive treatment for improving both maximal and pain-free walking distances [@saadi2025].
* **Antiplatelet therapy:** aspirin (75–325 mg daily) or clopidogrel (75 mg daily). The CAPRIE trial demonstrated clopidogrel superiority in the peripheral arterial disease (PAD) subgroup (8.7% relative risk reduction; p=0.0028) [@lancet1996].
* **Statin therapy:** high-intensity therapy (e.g., atorvastatin 40–80 mg) reduces cardiovascular events and limb events (HPS, SPARCL trials).[@hps2002, @amarenco2006] Target low-density lipoprotein (LDL) <70 mg/dL, or <55 mg/dL in very high-risk patients.patients [@acc2026-b].
* **Dual-pathway inhibition:** rivaroxaban 2.5 mg BID plus aspirin reduces major adverse cardiovascular events (MACE) and major adverse limb events (MALE) by 24% (COMPASS trial), with increased but manageable bleeding risk [@eikelboom2017].
* **Cilostazol:** phosphodiesterase-3 inhibitor that increases walking distance and improves quality of life;[@thompson2002, @saadi2025] 100 mg twice daily (not approved in Europe due to concerns about cardiac safety). The 2025 Society for Vascular Surgery (SVS) focused update reaffirms its efficacy for patients with intermittent claudication (IC) [@conte2025].
* **Post-revascularization antithrombotic therapy:** after lower extremity revascularization (LER), rivaroxaban 2.5 mg BID plus aspirin reduces acute limb ischemia (ALI) and MACE compared with aspirin alone (VOYAGER-PAD), balancing efficacy against increased bleeding risk in appropriate candidates [@voyager2020]. Recent evidence highlights significant practice variations in antithrombotic selection and the potential role of extended clopidogrel therapy [@wells2025].
Go to section in textbookDispute / Submit evidenceAll updates